PARSIPPANY, N.J.--(BUSINESS WIRE)--Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing oncology therapeutics, today announced that it has closed a private placement of its securities resulting in gross proceeds to the company of over $15 million. The financing included both new and existing investors and was lead by UTA Capital, LLC and Pontifax Funds. Riverbank Capital Inc., a FINRA member broker dealer, acted as placement agent.
